Dublin, Dec. 22, 2021 (GLOBE NEWSWIRE) -- The "Proto Oncogene Proteins C PIM 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Proto oncogene proteins c pim 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene proteins c pim 1 inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Proto oncogene proteins c pim 1 inhibitors.
Emerging Drugs Chapters
This segment of the Proto oncogene proteins c pim 1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
MEN 1703: Menarini Group
MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, and PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents. The spectrum of activity of MEN1703 also warrants the compound investigation in AML patients regardless of FLT3 aberrations. MEN1703 is being investigated as potential treatment for adult patients with relapsed/refractory AML in Phase II clinical trial.
This segment of the report provides insights about the different Proto oncogene proteins c pim 1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Proto oncogene proteins c pim 1 inhibitors. The companies which have their Proto oncogene proteins c pim 1 inhibitors drug candidates in the most advanced stage, i.e. phase II include Menarini Group.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proto oncogene proteins c pim 1 inhibitors therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene proteins c pim 1 inhibitors drugs.
Key Questions Answered
How many companies are developing Proto oncogene proteins c pim 1 inhibitors drugs?
How many Proto oncogene proteins c pim 1 inhibitors drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene proteins c pim 1 inhibitors?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene proteins c pim 1 inhibitors therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Proto oncogene proteins c pim 1 inhibitors and their status?
What are the key designations that have been granted to the emerging drugs?
Inflection Biosciences/AUM Biosciences
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/zbobky
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900